Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy
**Background:** Pulmonary arterial hypertension (PAH) is described by proliferation of small pulmonary arteries leading to increased pulmonary vascular resistance, right ventricular failure, and death. Research confirms long-term improvement in composite morbidity and mortality endpoints on some end...
Saved in:
Main Authors: | George Ruiz, Jason Yeaw, Cassandra A. Lickert, Ajita P. De, Rolin L. Wade, Janis Pruett, William Drake |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2018-01-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/9812 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Arduous management in treatment of elderly patient with pulmonary arterial hypertension and cardiopulmonary comorbidities
by: Yu Enomoto, et al.
Published: (2025-01-01) -
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension
by: Richard Channick, MD, et al.
Published: (2025-02-01) -
Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database
by: Ariel Berger, et al.
Published: (2014-02-01) -
Angiopoietin-2 and D-dimer add prognostic information to clinical risk in pulmonary arterial hypertension
by: Heather L. Clark, et al.
Published: (2025-02-01) -
Mendelian randomization study of serum uric acid levels and urate-lowering drugs on pulmonary arterial hypertension outcomes
by: Xiaoling Yao, et al.
Published: (2025-02-01)